A method of manufacturing a formulated pharmaceutical powder, the method comprising: a. atomizing an aqueous solution via a spray dryer, the aqueous solution comprising: i. 0.1%-2.0% (w/v) of a thermal stabilizer and 50 mg/mL to 180 mg/mL of a protein with a mass ratio at or between 1:5-2:5, wherein the thermal stabilizer is selected from sucrose, trehalose, mannitol, isoleucine, proline, or combinations thereof and the protein is (a) a Fc containing glycoprotein selected from an antibody or a receptor Fc fusion protein, or (b) a soluble receptor, and ii. 0.01-0.2% (w/v) of a nonionic surfactant selected from the group consisting of alkyl polyethylene oxide), alkyl polyglucosides, fatty alcohols, cocamide MEA, cocamide DEA, cocamide TEA, polyoxyethylene sorbitan esters, poloxamers, poloxamer 188, poloxamer 407, polyethylene-polypropylene glycol, and polyethylene glycol, wherein an inlet temperature of the spray dryer is set at a temperature of 100°C to 130°C and an outlet temperature of the spray dryer is set at a temperature that is below the boiling point of water and above ambient temperature; and b. applying heat to the atomized aqueous solution to form the formulated pharmaceutical powder, wherein the formulated pharmaceutical powder is not subjected to secondary drying, wherein the formulated pharmaceutical powder comprises between 3% to 10 (w/w) water. a. atomizing an aqueous solution via a spray dryer, the aqueous solution comprising: i. 0.1%-2.0% (w/v) of a thermal stabilizer and 50 mg/mL to 180 mg/mL of a protein with a mass ratio at or between 1:5-2:5, wherein the thermal stabilizer is selected from sucrose, trehalose, mannitol, isoleucine, proline, or combinations thereof and the protein is (a) a Fc containing glycoprotein selected from an antibody or a receptor Fc fusion protein, or (b) a soluble receptor, and ii. 0.01-0.2% (w/v) of a nonionic surfactant selected from the group consisting of alkyl polyethylene oxide), alkyl polyglucosides, fatty alcohols, cocamide MEA, cocamide DEA, cocamide TEA, polyoxyethylene sorbitan esters, poloxamers, poloxamer 188, poloxamer 407, polyethylene-polypropylene glycol, and polyethylene glycol, wherein an inlet temperature of the spray dryer is set at a temperature of 100°C to 130°C and an outlet temperature of the spray dryer is set at a temperature that is below the boiling point of water and above ambient temperature; and i. 0.1%-2.0% (w/v) of a thermal stabilizer and 50 mg/mL to 180 mg/mL of a protein with a mass ratio at or between 1:5-2:5, wherein the thermal stabilizer is selected from sucrose, trehalose, mannitol, isoleucine, proline, or combinations thereof and the protein is (a) a Fc containing glycoprotein selected from an antibody or a receptor Fc fusion protein, or (b) a soluble receptor, and ii. 0.01-0.2% (w/v) of a nonionic surfactant selected from the group consisting of alkyl polyethylene oxide), alkyl polyglucosides, fatty alcohols, cocamide MEA, cocamide DEA, cocamide TEA, polyoxyethylene sorbitan esters, poloxamers, poloxamer 188, poloxamer 407, polyethylene-polypropylene glycol, and polyethylene glycol, b. applying heat to the atomized aqueous solution to form the formulated pharmaceutical powder, wherein the formulated pharmaceutical powder is not subjected to secondary drying, wherein the formulated pharmaceutical powder comprises between 3% to 10 (w/w) water.